Core Insights - Cloud-based innovative pharmaceutical company, CloudTop New Horizon, has signed an exclusive licensing agreement with Visara for the clinical development, production, and commercialization of VIS-101 in Greater China, Singapore, South Korea, and parts of Southeast Asia, marking its entry into the ophthalmology treatment sector [1][2] - The CEO of CloudTop New Horizon emphasized that VIS-101 has high differentiation and commercial potential, which will enrich the company's product pipeline and expand its business into the ophthalmology market [1] - The agreement includes a $7 million upfront payment, reimbursement of up to 24 million RMB in self-paid expenses, potential milestone payments of up to $89 million, and royalties based on net sales [1] Company Developments - Visara, a subsidiary of New Bridge Bio (formerly I-Mab), is involved in this licensing agreement, with CloudTop New Horizon being the largest shareholder of New Bridge Bio [2] - The CEO of New Bridge Bio stated that this authorization is a significant step in optimizing global commercial layout and promoting global clinical development collaboration [2] - VIS-101 is a novel dual-function biologic targeting VEGF-A and ANG-2, showing improved efficacy over first-generation treatments, and is expected to provide lasting treatment benefits for patients with wet AMD, DME, and RVO [2] Market Potential - The ophthalmic drug market is experiencing rapid growth, with the global anti-VEGF ophthalmic drug market projected to reach approximately $23 billion in 2024 and exceed $40 billion by 2030 [3] - In China, there is a significant unmet clinical need in the retinal disease market, with over 15 million existing and new patients for wet AMD, DME, and RVO, but only about 500,000 currently receiving anti-VEGF treatment [3] - The company plans to introduce at least three more major products, with expected peak sales in the domestic market exceeding 10 billion RMB, and overall domestic sales potentially surpassing 20 billion RMB [3]
云顶新耀引进眼科双抗药物VIS-101 切入高潜力眼科蓝海市场